This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
The sample size and power calculations were reported. A sample size of 43 patients in each arm was needed to give a power of 80% for detecting a 25% difference in acute rejection with a significance level of 5%. The method of sample selection was stated to be sequential. Fifty patients were enrolled in each sequential cohort, the majority of which were men (70% in the C2 group and 62% in the C0 group). The mean average age was 51 (+/-12) years in the C2 group and 43 (+/-14) years in the C0 group.
Study design
This was a prospective, sequentially designed, cohort trial that was conducted in a single centre. The follow-up period was 6 months after transplant. No loss to follow-up was reported. Blinded assessment was not reported.
Analysis of effectiveness
The primary end point of the study was the rate of acute rejection at 6 months. The secondary end points were allograft function, infection and adverse events. The analysis of the clinical study was conducted on an intention to treat basis. Univariate analyses were performed, using Student's t-test for continuous variables and the chi-squared test for categorical variables. All statistical tests were two-tailed. The patients in the C2 group tended to be older, (p=0.08), but were similar in other baseline characteristics (e.g. white origin, gender, type of donor).
Effectiveness results
Patient and graft survivals were 100% in both groups at 6 months.
The incidence (4% versus 6%; p non significant) and severity of acute rejection were similar between the two groups. One patient in the C2 arm and two patients in the C0 arm demonstrated a Banff Grade IB, steroid-sensitive rejection 3 months after transplant. One patient in the C2 arm demonstrated a Grade IIB rejection 14 days after transplantation, while one in the C0 arm demonstrated a Grade IIA rejection 7 days after transplantation. The mean serum creatinine at 6 months after transplantation was 1.5 (+/-0.5) mg/dL in the C2 arm, and 1.5 (+/-0.6 mg/dL) in the C0 arm, (p non significant).
The mean blood pressures in both groups improved after transplantation. There were no serious fungal or viral infections, including cytomegalovirus, during the study period. The incidence of bacterial infections was similar between the groups. There were no occurrences of malignancy. Post-transplant diabetes mellitus occurred in one patient in each arm.
Lower cyclosporine doses were achieved in the C2 arm than in C0 arm by one month after transplantation, and these were sustained throughout the 6-month study period. At one month, the mean cyclosporine dose was 390 (+/-116) mg/day in the C2 arm versus the 453 (+/-161) mg/day in the C0 arm, (p<0.05). A similar trend continued at 6 months with average doses of 199 (+/-73) mg/day in the C2 arm versus 273 (+/-104) mg/day in the C0 arm, (p<0.001).
The C2 levels were lower than international guidelines throughout the study period. More specifically, 33% lower at one month, 38% lower at 3 months, and 48% lower at 6 months.
Clinical conclusions
According to the authors, the major finding of the study was that a quadruple immunosuppressive regimen with cyclosporine monitored by C2 concentrations, which were lower than internationally recommended guidelines, prevented acute rejection and minimised toxicity. Patient and graft survival were excellent in this 6-month trial. Allograft function was also excellent, with low acute rejection rates and low serum creatinine values. Although the follow-up was brief, it is possible that lower C2 concentrations might decrease the risk of long-term complications such as infection or malignancy.
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Measure of benefits used in the economic analysis
As the clinical results were similar between the groups, the authors reported cost-differences. The paper was, in effect, a cost-minimisation analysis.
Direct costs
The only direct costs included in the study were those of immunosuppressive medications and other medications. Drug costs were calculated with the exclusion of antibody agents, antiviral therapy for prophylaxis and short-term antibiotic treatments, although the use of these agents was similar between the groups. The medication costs were based on the average wholesale price. The costs and the quantities were estimated from actual data. The 12-month medication cost was calculated from the actual cost of immunosuppression and concomitant medications during months 0 to 6 after transplant plus the expected costs during months 6 to 12, postoperatively determined from the 6-month medication cost. Discounting was not carried out since the costs were incurred during less than two years. The quantities and the costs were not analysed separately. The price year was 2003.
Statistical analysis of costs
The costs were treated stochastically. Univariate analyses were performed, using Student's t-test for continuous variables and the chi-squared test for categorical variables. All statistical tests were two-tailed.
Indirect Costs
No indirect costs were reported.
Currency

US dollars ($).
Sensitivity analysis
No sensitivity analysis was reported.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
During the first 6 months, cyclosporine monitored by C2 concentrations was less expensive than cyclosporine monitored by C0. The costs of cyclosporine were $2,811 (+/-933) in the C2 arm versus $3,584 (+/-1,363) in the C0 arm, (p=0.001).
The total 6-month immunosuppression costs were lower in the C2 arm than in the C0 arm, $3,981 (+/-1,123) versus $4,809 (+/-1,575), (p=0.003). This translated into average cost-savings for C2-monitored patients of $773 in cyclosporine costs, (p<0.001), and $828 in total immunosuppressive costs, (p<0.001).
At 6 months, the cumulative immunosuppressive and concomitant medication costs were lower in the C2 arm than in the C0 arm, $7,551 (+/-3,639) versus $8,111 (+/-3,898), but were not statistically significant.
The estimated 12-month cost and use of concomitant medications was not statistically different, $13,457 (+/-8,634) in the C2 group versus $14,462 (+/-7,233) in the C0 group.
